25 XP   0   0   10

Kala Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Kala Pharmaceuticals Inc together

PenkeI guess you are interested in Kala Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kala Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kala Pharmaceuticals Inc

I send you an email if I find something interesting about Kala Pharmaceuticals Inc.

Quick analysis of Kala Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Kala Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
6.1%

What is your share worth?

Current worth
$2.77
Expected worth in 1 year
$-1.51
How sure are you?
27.3%

+ What do you gain per year?

Total Gains per Share
$-4.28
Return On Investment
-62.8%

For what price can you sell your share?

Current Price per Share
$6.81
Expected price per share
$6.485 - $9.25
How sure are you?
50%

1. Valuation of Kala Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$6.81

Intrinsic Value Per Share

$122.39 - $159.28

Total Value Per Share

$125.16 - $162.05

2. Growth of Kala Pharmaceuticals Inc (5 min.)




Is Kala Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$7.5m-$4.7m$19.6m131.6%

How much money is Kala Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11.6m-$170k-$11.4m-98.5%
Net Profit Margin-3,081.1%3,163.7%--

How much money comes from the company's main activities?

3. Financial Health of Kala Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Kala Pharmaceuticals Inc? (5 min.)

Welcome investor! Kala Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Kala Pharmaceuticals Inc.

What can you expect buying and holding a share of Kala Pharmaceuticals Inc?

First you should know what it really means to hold a share of Kala Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Kala Pharmaceuticals Inc is $6.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kala Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kala Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.77. Based on the TTM, the Book Value Change Per Share is $-1.07 per quarter. Based on the YOY, the Book Value Change Per Share is $0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kala Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.18-46.7%-3.91-57.4%-4.16-61.1%-7.95-116.7%-6.80-99.9%
Usd Book Value Change Per Share-1.40-20.6%-1.07-15.7%0.203.0%-1.81-26.6%0.081.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.2%0.010.1%
Usd Total Gains Per Share-1.40-20.6%-1.07-15.7%0.203.0%-1.80-26.4%0.091.4%
Usd Price Per Share7.00-11.39-10.01-7.86-7.36-
Price to Earnings Ratio-0.55--0.72--0.51--0.34--0.41-
Price-to-Total Gains Ratio-5.00--1.59-1.24--0.48--0.49-
Price to Book Ratio2.53-2.16-1.02-0.76-0.68-
Price-to-Total Gains Ratio-5.00--1.59-1.24--0.48--0.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.81
Number of shares146
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-1.07-1.81
Usd Total Gains Per Share-1.07-1.80
Gains per Quarter (146 shares)-156.18-262.27
Gains per Year (146 shares)-624.72-1,049.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-625-6358-1058-1059
20-1249-126017-2115-2108
30-1874-188525-3173-3157
40-2499-251034-4230-4206
50-3124-313542-5288-5255
60-3748-376051-6345-6304
70-4373-438559-7403-7353
80-4998-501068-8460-8402
90-5622-563576-9518-9451
100-6247-626085-10575-10500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.032.00.03.0%1.032.00.03.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%9.021.03.027.3%9.021.03.027.3%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.031.06.1%2.00.031.06.1%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%9.021.03.027.3%9.021.03.027.3%

Fundamentals of Kala Pharmaceuticals Inc

About Kala Pharmaceuticals Inc

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 12:35:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kala Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kala Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -12,324.3% means that $-123.24 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kala Pharmaceuticals Inc:

  • The MRQ is -12,324.3%. The company is making a huge loss. -2
  • The TTM is -3,081.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-12,324.3%TTM-3,081.1%-9,243.2%
TTM-3,081.1%YOY3,163.7%-6,244.8%
TTM-3,081.1%5Y-961.1%-2,119.9%
5Y-961.1%10Y-1,705.9%+744.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12,324.3%-197.2%-12,127.1%
TTM-3,081.1%-210.4%-2,870.7%
YOY3,163.7%-279.3%+3,443.0%
5Y-961.1%-436.8%-524.3%
10Y-1,705.9%-599.3%-1,106.6%
1.1.2. Return on Assets

Shows how efficient Kala Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • -15.4% Return on Assets means that Kala Pharmaceuticals Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kala Pharmaceuticals Inc:

  • The MRQ is -15.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-17.8%+2.4%
TTM-17.8%YOY2.0%-19.8%
TTM-17.8%5Y-12.1%-5.7%
5Y-12.1%10Y-26.9%+14.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-13.6%-1.8%
TTM-17.8%-12.9%-4.9%
YOY2.0%-11.9%+13.9%
5Y-12.1%-14.2%+2.1%
10Y-26.9%-16.2%-10.7%
1.1.3. Return on Equity

Shows how efficient Kala Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • -115.0% Return on Equity means Kala Pharmaceuticals Inc generated $-1.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kala Pharmaceuticals Inc:

  • The MRQ is -115.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -82.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-115.0%TTM-82.9%-32.0%
TTM-82.9%YOY-18.3%-64.7%
TTM-82.9%5Y-54.7%-28.3%
5Y-54.7%10Y-37.8%-16.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-115.0%-17.0%-98.0%
TTM-82.9%-16.1%-66.8%
YOY-18.3%-15.4%-2.9%
5Y-54.7%-20.0%-34.7%
10Y-37.8%-21.1%-16.7%

1.2. Operating Efficiency of Kala Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kala Pharmaceuticals Inc is operating .

  • Measures how much profit Kala Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -13,344.3% means the company generated $-133.44  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kala Pharmaceuticals Inc:

  • The MRQ is -13,344.3%. The company is operating very inefficient. -2
  • The TTM is -3,336.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-13,344.3%TTM-3,336.1%-10,008.2%
TTM-3,336.1%YOY-1,955.1%-1,381.0%
TTM-3,336.1%5Y-1,896.0%-1,440.1%
5Y-1,896.0%10Y-2,222.9%+326.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13,344.3%-286.1%-13,058.2%
TTM-3,336.1%-224.4%-3,111.7%
YOY-1,955.1%-288.4%-1,666.7%
5Y-1,896.0%-475.2%-1,420.8%
10Y-2,222.9%-624.7%-1,598.2%
1.2.2. Operating Ratio

Measures how efficient Kala Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 133.44 means that the operating costs are $133.44 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kala Pharmaceuticals Inc:

  • The MRQ is 133.443. The company is inefficient in keeping operating costs low. -1
  • The TTM is 33.361. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ133.443TTM33.361+100.082
TTM33.361YOY20.599+12.762
TTM33.3615Y19.885+13.476
5Y19.88510Y33.366-13.481
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ133.4432.997+130.446
TTM33.3613.247+30.114
YOY20.5993.766+16.833
5Y19.8855.675+14.210
10Y33.3667.857+25.509

1.3. Liquidity of Kala Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kala Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.33 means the company has $6.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kala Pharmaceuticals Inc:

  • The MRQ is 6.335. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.390. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.335TTM6.390-0.055
TTM6.390YOY2.747+3.642
TTM6.3905Y6.492-0.102
5Y6.49210Y6.117+0.374
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3353.930+2.405
TTM6.3904.251+2.139
YOY2.7475.436-2.689
5Y6.4926.045+0.447
10Y6.1176.363-0.246
1.3.2. Quick Ratio

Measures if Kala Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 18.07 means the company can pay off $18.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kala Pharmaceuticals Inc:

  • The MRQ is 18.067. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.221. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.067TTM9.221+8.846
TTM9.221YOY2.275+6.947
TTM9.2215Y7.403+1.819
5Y7.40310Y6.587+0.816
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.0673.629+14.438
TTM9.2214.065+5.156
YOY2.2755.397-3.122
5Y7.4035.993+1.410
10Y6.5876.277+0.310

1.4. Solvency of Kala Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kala Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kala Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.87 means that Kala Pharmaceuticals Inc assets are financed with 86.6% credit (debt) and the remaining percentage (100% - 86.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kala Pharmaceuticals Inc:

  • The MRQ is 0.866. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.774. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.866TTM0.774+0.092
TTM0.774YOY1.053-0.279
TTM0.7745Y0.739+0.034
5Y0.73910Y0.951-0.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8660.332+0.534
TTM0.7740.334+0.440
YOY1.0530.268+0.785
5Y0.7390.366+0.373
10Y0.9510.390+0.561
1.4.2. Debt to Equity Ratio

Measures if Kala Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 645.6% means that company has $6.46 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kala Pharmaceuticals Inc:

  • The MRQ is 6.456. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.946. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ6.456TTM3.946+2.510
TTM3.946YOY0.894+3.052
TTM3.9465Y2.289+1.656
5Y2.28910Y1.495+0.794
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4560.381+6.075
TTM3.9460.390+3.556
YOY0.8940.334+0.560
5Y2.2890.434+1.855
10Y1.4950.466+1.029

2. Market Valuation of Kala Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kala Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Kala Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.55 means the investor is paying $-0.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kala Pharmaceuticals Inc:

  • The EOD is -0.535. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.550. Based on the earnings, the company is expensive. -2
  • The TTM is -0.721. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.535MRQ-0.550+0.015
MRQ-0.550TTM-0.721+0.171
TTM-0.721YOY-0.508-0.213
TTM-0.7215Y-0.338-0.382
5Y-0.33810Y-0.412+0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.535-2.315+1.780
MRQ-0.550-2.560+2.010
TTM-0.721-2.664+1.943
YOY-0.508-4.122+3.614
5Y-0.338-6.258+5.920
10Y-0.412-6.108+5.696
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kala Pharmaceuticals Inc:

  • The EOD is -0.600. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.616. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.191. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.600MRQ-0.616+0.017
MRQ-0.616TTM-1.191+0.574
TTM-1.191YOY-0.481-0.710
TTM-1.1915Y-0.436-0.754
5Y-0.43610Y-0.911+0.475
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.600-3.067+2.467
MRQ-0.616-3.251+2.635
TTM-1.191-3.545+2.354
YOY-0.481-5.595+5.114
5Y-0.436-8.315+7.879
10Y-0.911-8.708+7.797
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kala Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.53 means the investor is paying $2.53 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kala Pharmaceuticals Inc:

  • The EOD is 2.462. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.530. Based on the equity, the company is underpriced. +1
  • The TTM is 2.160. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.462MRQ2.530-0.069
MRQ2.530TTM2.160+0.370
TTM2.160YOY1.017+1.143
TTM2.1605Y0.762+1.398
5Y0.76210Y0.683+0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4621.905+0.557
MRQ2.5302.111+0.419
TTM2.1602.095+0.065
YOY1.0172.836-1.819
5Y0.7623.443-2.681
10Y0.6833.794-3.111
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kala Pharmaceuticals Inc.

3.1. Institutions holding Kala Pharmaceuticals Inc

Institutions are holding 23.782% of the shares of Kala Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP9.89980.021226661300
2023-12-31Millennium Management LLC4.92640.0004132674-1680-1.2504
2023-12-31Vanguard Group Inc1.0410280359073.3434
2023-12-31BlackRock Inc1.014502732112224.6822
2023-12-31Board of Ttees Leland Stanford Jr Univ0.78450.00962112700
2023-12-31Geode Capital Management, LLC0.685601846500
2023-12-31Renaissance Technologies Corp0.52360.000214100141000
2023-12-31Knights of Columbus Asset Advisors LLC0.17950.002248342417100
2023-12-31Tower Research Capital LLC0.16180.0004435743570
2023-12-31Bank of America Corp0.09610258724722149.5652
2023-12-31Morgan Stanley - Brokerage Accounts0.060201621-32-1.9359
2023-12-31Covestor Ltd0.04690.00621262-63-4.7547
2023-12-31Banque Cantonale Vaudoise0.030.000380800
2023-12-31UBS Group AG0.02580696551380
2023-12-31Compagnie Lombard, Odier SCA0.01490.000140000
2023-12-31Citigroup Inc0.011029600
2023-12-31Advisor Group Holdings, Inc.0.0089024172.9915
2023-12-31CWM, LLC duplicate0.0074020000
2023-12-31Steward Partners Investment Advisory, LLC0.0045012000
2023-12-31Royal Bank of Canada0.002306349350
Total 19.52470.0406525820+24307+4.6%

3.2. Funds holding Kala Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.93370.00022629600
2024-02-29Vanguard Total Stock Mkt Idx Inv0.5274014853632174.0858
2024-02-29Fidelity Extended Market Index0.3910.000211012-53-0.479
2023-09-30BlackRock Extended Mkt Composite0.37630.00071059700
2024-03-31BlackRock Extended Equity Market K0.32840.0005924830.0324
2024-03-28iShares Micro-Cap ETF0.19350.0047545000
2023-12-31Bridgeway Ultra-Small Company Market0.12430.0132350000
2024-02-29Fidelity Series Total Market Index0.08930251400
2024-02-29Fidelity Total Market Index0.0790222500
2024-02-29Fidelity Nasdaq Composite Index0.05260.0001148200
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04160.0001117200
2023-12-31Northern Trust Extended Eq Market Idx0.04160.0001117200
2024-03-31Extended Equity Market Fund M0.04050.00051141-2-0.175
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03440.000196800
2024-02-29Spartan Total Market Index Pool E0.032090200
2024-02-29Vanguard U.S. Eq Idx £ Acc0.0295083200
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02760.000177710.1289
2024-03-31BlackRock U.S. Equity Market F0.0198055850.9042
2024-03-31State St US Extended Mkt Indx NL Cl C0.01520.000242800
2023-12-31SSgA U.S. Extended Market Index Class I0.01520.000142800
Total 3.39290.020895555+6275+6.6%

3.3. Insider Transactions

Insiders are holding 18.768% of the shares of Kala Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-04Eric TrachtenbergSELL12276.74
2024-01-04Mark T IwickiSELL45396.73

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kala Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.401-1.070-24%0.201-795%-1.811+29%0.084-1771%
Book Value Per Share--2.7665.535-50%-1.748+163%18.673-85%13.911-80%
Current Ratio--6.3356.390-1%2.747+131%6.492-2%6.117+4%
Debt To Asset Ratio--0.8660.774+12%1.053-18%0.739+17%0.951-9%
Debt To Equity Ratio--6.4563.946+64%0.894+622%2.289+182%1.495+332%
Dividend Per Share----0%-0%0.014-100%0.009-100%
Eps---3.180-3.912+23%-4.161+31%-7.951+150%-6.801+114%
Free Cash Flow Per Share---2.840-2.644-7%-7.354+159%-7.492+164%-5.899+108%
Free Cash Flow To Equity Per Share---1.905-1.856-3%-8.091+325%-3.542+86%-0.082-96%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--159.279--------
Intrinsic Value_10Y_min--122.394--------
Intrinsic Value_1Y_max---20.670--------
Intrinsic Value_1Y_min---20.325--------
Intrinsic Value_3Y_max---34.189--------
Intrinsic Value_3Y_min---33.203--------
Intrinsic Value_5Y_max---14.051--------
Intrinsic Value_5Y_min---15.444--------
Market Cap18340147.200-4%18987325.00030695042.450-38%26966951.168-30%21182736.413-10%32074320.622-41%
Net Profit Margin---123.243-30.811-75%31.637-490%-9.611-92%-17.059-86%
Operating Margin---133.443-33.361-75%-19.551-85%-18.960-86%-22.229-83%
Operating Ratio--133.44333.361+300%20.599+548%19.885+571%33.366+300%
Pb Ratio2.462-3%2.5302.160+17%1.017+149%0.762+232%0.683+270%
Pe Ratio-0.535+3%-0.550-0.721+31%-0.508-8%-0.338-39%-0.412-25%
Price Per Share6.810-3%7.00011.385-39%10.013-30%7.863-11%7.363-5%
Price To Free Cash Flow Ratio-0.600+3%-0.616-1.191+93%-0.481-22%-0.436-29%-0.911+48%
Price To Total Gains Ratio-4.861+3%-4.997-1.593-68%1.243-502%-0.478-90%-0.491-90%
Quick Ratio--18.0679.221+96%2.275+694%7.403+144%6.587+174%
Return On Assets---0.154-0.178+15%0.020-864%-0.121-22%-0.269+74%
Return On Equity---1.150-0.829-28%-0.183-84%-0.547-52%-0.378-67%
Total Gains Per Share---1.401-1.070-24%0.201-795%-1.796+28%0.093-1612%
Usd Book Value--7504000.00014920000.000-50%-4708000.000+163%50292100.000-85%39884575.758-81%
Usd Book Value Change Per Share---1.401-1.070-24%0.201-795%-1.811+29%0.084-1771%
Usd Book Value Per Share--2.7665.535-50%-1.748+163%18.673-85%13.911-80%
Usd Dividend Per Share----0%-0%0.014-100%0.009-100%
Usd Eps---3.180-3.912+23%-4.161+31%-7.951+150%-6.801+114%
Usd Free Cash Flow---7703000.000-7134250.000-7%-19805250.000+157%-20178500.000+162%-16074212.121+109%
Usd Free Cash Flow Per Share---2.840-2.644-7%-7.354+159%-7.492+164%-5.899+108%
Usd Free Cash Flow To Equity Per Share---1.905-1.856-3%-8.091+325%-3.542+86%-0.082-96%
Usd Market Cap18340147.200-4%18987325.00030695042.450-38%26966951.168-30%21182736.413-10%32074320.622-41%
Usd Price Per Share6.810-3%7.00011.385-39%10.013-30%7.863-11%7.363-5%
Usd Profit---8627000.000-11611250.000+35%-170000.000-98%-19420200.000+125%-16581636.364+92%
Usd Revenue--70000.00017500.000+300%1280000.000-95%1443300.000-95%876090.909-92%
Usd Total Gains Per Share---1.401-1.070-24%0.201-795%-1.796+28%0.093-1612%
 EOD+3 -5MRQTTM+7 -26YOY+16 -175Y+16 -1910Y+12 -23

4.2. Fundamental Score

Let's check the fundamental score of Kala Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.535
Price to Book Ratio (EOD)Between0-12.462
Net Profit Margin (MRQ)Greater than0-123.243
Operating Margin (MRQ)Greater than0-133.443
Quick Ratio (MRQ)Greater than118.067
Current Ratio (MRQ)Greater than16.335
Debt to Asset Ratio (MRQ)Less than10.866
Debt to Equity Ratio (MRQ)Less than16.456
Return on Equity (MRQ)Greater than0.15-1.150
Return on Assets (MRQ)Greater than0.05-0.154
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Kala Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.203
Ma 20Greater thanMa 507.549
Ma 50Greater thanMa 1007.441
Ma 100Greater thanMa 2007.298
OpenGreater thanClose6.900
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  462-90372-44328-14314-615-301



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets55,949
Total Liabilities48,445
Total Stockholder Equity7,504
 As reported
Total Liabilities 48,445
Total Stockholder Equity+ 7,504
Total Assets = 55,949

Assets

Total Assets55,949
Total Current Assets52,870
Long-term Assets3,079
Total Current Assets
Cash And Cash Equivalents 50,895
Short-term Investments 99,657
Net Receivables 236
Total Current Assets  (as reported)52,870
Total Current Assets  (calculated)150,788
+/- 97,918
Long-term Assets
Property Plant Equipment 2,778
Long-term Assets Other -301
Long-term Assets  (as reported)3,079
Long-term Assets  (calculated)2,477
+/- 602

Liabilities & Shareholders' Equity

Total Current Liabilities8,346
Long-term Liabilities40,099
Total Stockholder Equity7,504
Total Current Liabilities
Short-term Debt 334
Accounts payable 919
Other Current Liabilities 6,018
Total Current Liabilities  (as reported)8,346
Total Current Liabilities  (calculated)7,271
+/- 1,075
Long-term Liabilities
Long term Debt 34,190
Capital Lease Obligations Min Short Term Debt1,799
Long-term Liabilities Other 4,110
Long-term Liabilities  (as reported)40,099
Long-term Liabilities  (calculated)40,099
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -629,409
Other Stockholders Equity 636,910
Total Stockholder Equity (as reported)7,504
Total Stockholder Equity (calculated)7,504
+/-0
Other
Capital Stock3
Cash and Short Term Investments 50,895
Common Stock Shares Outstanding 2,712
Current Deferred Revenue1,075
Liabilities and Stockholders Equity 55,949
Net Debt -14,572
Net Invested Capital 41,694
Net Working Capital 44,524
Property Plant and Equipment Gross 3,888
Short Long Term Debt Total 36,323



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
8,448
0
0
0
46,329
37,608
28,591
123,691
116,133
116,133
95,590
84,075
220,966
197,016
178,815
161,013
154,323
258,526
245,510
225,096
221,606
229,827
215,464
193,814
139,427
111,574
84,976
85,698
86,820
72,226
66,500
61,120
55,949
55,94961,12066,50072,22686,82085,69884,976111,574139,427193,814215,464229,827221,606225,096245,510258,526154,323161,013178,815197,016220,96684,07595,590116,133116,133123,69128,59137,60846,3290008,448
   > Total Current Assets 
7,601
0
0
0
45,626
36,902
27,894
122,935
115,213
115,213
91,936
80,455
177,028
150,449
132,803
112,486
105,484
210,247
197,024
178,156
171,379
179,065
171,720
149,086
124,366
98,255
83,515
84,672
85,942
71,344
65,535
57,902
52,870
52,87057,90265,53571,34485,94284,67283,51598,255124,366149,086171,720179,065171,379178,156197,024210,247105,484112,486132,803150,449177,02880,45591,936115,213115,213122,93527,89436,90245,6260007,601
       Cash And Cash Equivalents 
5,759
0
0
0
45,472
36,024
26,350
122,049
114,565
114,565
91,205
74,910
170,898
138,944
118,006
97,556
85,449
196,456
128,023
45,526
77,264
127,970
144,635
124,503
92,136
65,170
42,569
52,393
70,495
63,636
49,256
56,063
50,895
50,89556,06349,25663,63670,49552,39342,56965,17092,136124,503144,635127,97077,26445,526128,023196,45685,44997,556118,006138,944170,89874,91091,205114,565114,565122,04926,35036,02445,4720005,759
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
699
0
56,536
113,594
76,276
28,015
5,000
0
0
4,992
1,999
0
0
0
9,922
0
99,657
99,65709,9220001,9994,992005,00028,01576,276113,59456,53606990000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
1,026
4,674
5,648
7,171
13,098
4,794
4,281
7,455
9,854
12,206
11,859
12,630
17,455
13,020
13,822
10,923
6,497
1,078
306
272
236
2362723061,0786,49710,92313,82213,02017,45512,63011,85912,2069,8547,4554,2814,79413,0987,1715,6484,6741,026000000000000
       Other Current Assets 
1,842
0
0
0
154
149
302
886
648
648
731
4,569
1,009
1,416
930
2,202
1,590
3,725
2,473
4,043
2,150
2,633
2,180
4,245
3,183
4,542
25,100
11,694
1,278
1,275
807
1,567
1,739
1,7391,5678071,2751,27811,69425,1004,5423,1834,2452,1802,6332,1504,0432,4733,7251,5902,2029301,4161,0094,5697316486488863021491540001,842
   > Long-term Assets 
0
0
0
0
703
706
697
756
920
920
3,654
3,620
43,938
46,567
46,012
48,527
48,839
48,279
48,486
46,940
50,227
50,762
43,744
44,728
15,061
13,319
1,461
1,026
878
882
965
3,218
3,079
3,0793,2189658828781,0261,46113,31915,06144,72843,74450,76250,22746,94048,48648,27948,83948,52746,01246,56743,9383,6203,6549209207566977067030000
       Property Plant Equipment 
738
0
0
0
594
597
563
623
786
786
1,476
1,442
31,732
33,992
33,434
32,947
32,479
31,874
31,793
31,166
31,019
31,584
31,369
30,481
4,021
4,089
942
551
416
510
637
2,904
2,778
2,7782,9046375104165519424,0894,02130,48131,36931,58431,01931,16631,79331,87432,47932,94733,43433,99231,7321,4421,476786786623563597594000738
       Long-term Assets Other 
0
0
0
0
109
109
134
133
134
134
2,178
2,178
12,206
12,575
12,578
15,580
16,360
16,405
16,693
15,774
19,208
19,178
12,375
14,247
11,040
9,230
519
475
462
372
328
314
-301
-3013143283724624755199,23011,04014,24712,37519,17819,20815,77416,69316,40516,36015,58012,57812,57512,2062,1782,1781341341331341091090000
> Total Liabilities 
14,241
0
0
0
134,091
15,141
136,010
24,828
26,454
26,454
27,497
29,141
115,979
114,649
117,749
117,957
124,631
117,016
116,567
119,066
121,611
120,035
131,194
132,345
122,623
116,858
116,530
86,666
67,846
48,765
49,008
49,897
48,445
48,44549,89749,00848,76567,84686,666116,530116,858122,623132,345131,194120,035121,611119,066116,567117,016124,631117,957117,749114,649115,97929,14127,49726,45426,45424,828136,01015,141134,09100014,241
   > Total Current Liabilities 
5,507
0
0
0
5,546
6,813
7,850
11,184
14,458
14,458
9,397
12,685
17,010
14,602
17,701
17,996
24,774
17,273
16,940
19,550
22,225
19,989
26,076
27,195
37,422
32,758
32,891
40,241
25,685
10,265
9,851
10,301
8,346
8,34610,3019,85110,26525,68540,24132,89132,75837,42227,19526,07619,98922,22519,55016,94017,27324,77417,99617,70114,60217,01012,6859,39714,45814,45811,1847,8506,8135,5460005,507
       Short-term Debt 
2,000
0
0
0
556
1,389
2,222
6,111
6,667
6,667
1,869
3,434
463
1,620
1,627
1,279
1,327
1,375
1,425
1,477
1,530
1,985
1,977
1,885
711
625
52
32
5,013
3
-4,189
324
334
334324-4,18935,01332526257111,8851,9771,9851,5301,4771,4251,3751,3271,2791,6271,6204633,4341,8696,6676,6676,1112,2221,3895560002,000
       Short Long Term Debt 
2,000
0
0
0
556
1,389
9,710
6,111
6,667
300
1,667
3,333
463
1,620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
0
0
0
00005,000000000000000001,6204633,3331,6673006,6676,1119,7101,3895560002,000
       Accounts payable 
1,404
0
0
0
997
2,317
1,325
1,135
7,791
1,202
2,382
1,283
5,446
2,647
3,196
2,162
2,518
1,187
1,548
2,222
1,724
2,855
2,844
5,845
4,899
6,218
10,542
7,348
2,832
997
760
787
919
9197877609972,8327,34810,5426,2184,8995,8452,8442,8551,7242,2221,5481,1872,5182,1623,1962,6475,4461,2832,3821,2027,7911,1351,3252,3179970001,404
       Other Current Liabilities 
2,103
0
0
0
3,993
3,107
4,303
3,938
6,589
6,589
5,146
7,968
11,101
10,335
12,878
14,555
20,929
14,711
13,967
15,851
18,971
15,149
21,255
19,465
3,817
25,915
22,297
29,453
13,651
5,076
9,091
6,260
6,018
6,0186,2609,0915,07613,65129,45322,29725,9153,81719,46521,25515,14918,97115,85113,96714,71120,92914,55512,87810,33511,1017,9685,1466,5896,5893,9384,3033,1073,9930002,103
   > Long-term Liabilities 
0
0
0
0
128,545
8,328
128,160
13,644
11,996
11,996
18,100
16,456
98,978
100,047
100,048
99,961
99,857
99,743
99,627
99,516
99,386
100,046
105,118
105,150
85,201
84,100
83,639
46,425
42,161
38,500
39,157
39,596
40,099
40,09939,59639,15738,50042,16146,42583,63984,10085,201105,150105,118100,04699,38699,51699,62799,74399,85799,961100,048100,04798,97816,45618,10011,99611,99613,644128,1608,328128,5450000
       Long term Debt Total 
0
0
0
0
0
0
7,488
13,629
11,987
19,746
18,100
16,456
98,978
70,457
70,692
70,935
71,184
71,438
71,697
71,967
72,243
72,521
78,055
78,491
0
0
0
0
0
33,266
33,569
0
0
0033,56933,2660000078,49178,05572,52172,24371,96771,69771,43871,18470,93570,69270,45798,97816,45618,10019,74611,98713,6297,488000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
28,752
31,210
30,983
30,305
30,000
29,680
29,355
29,026
28,673
29,510
29,040
28,544
1,259
1,362
52
32
13
3
0
2,204
2,133
2,1332,204031332521,3621,25928,54429,04029,51028,67329,02629,35529,68030,00030,30530,98331,21028,752000000000000
       Warrants
0
0
0
0
0
0
118,391
21,801
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000021,801118,391000000
       Long-term Liabilities Other 
0
0
0
0
0
0
2,281
15
9
0
0
0
0
29,590
29,356
29,026
28,673
28,305
27,930
27,549
27,143
27,525
27,063
26,659
4,841
4,002
3,839
3,783
4,224
5,234
5,588
3,838
4,110
4,1103,8385,5885,2344,2243,7833,8394,0024,84126,65927,06327,52527,14327,54927,93028,30528,67329,02629,35629,59000009152,281000000
> Total Stockholder Equity
-56,664
0
0
0
-87,762
22,467
-107,419
98,863
89,679
89,679
68,093
54,934
104,987
82,367
61,066
43,056
29,692
141,510
128,943
106,030
99,995
109,792
84,270
61,469
16,804
-5,284
-31,554
-968
18,974
23,461
17,492
11,223
7,504
7,50411,22317,49223,46118,974-968-31,554-5,28416,80461,46984,270109,79299,995106,030128,943141,51029,69243,05661,06682,367104,98754,93468,09389,67989,67998,863-107,41922,467-87,762000-56,664
   Common Stock
1
0
0
0
1
17
1
24
25
25
25
25
34
34
34
35
36
55
56
56
59
64
65
65
66
73
73
1
2
2
3
3
3
333221737366656564595656553635343434252525252411710001
   Retained Earnings -629,409-620,782-612,078-601,665-587,210-574,367-603,440-575,329-542,388-494,820-466,693-430,195-399,783-368,671-340,723-317,411-295,456-273,498-250,322-226,497-201,109-175,890-160,287-134,371-134,371-123,081-112,905-101,919-92,137000-58,970
   Capital Surplus 
0
0
0
0
0
0
5,485
221,920
224,025
225,914
228,355
230,799
306,053
308,830
311,354
316,519
325,112
458,866
469,627
474,648
499,715
539,920
550,898
556,224
0
0
0
0
0
625,124
629,558
0
0
00629,558625,12400000556,224550,898539,920499,715474,648469,627458,866325,112316,519311,354308,830306,053230,799228,355225,914224,025221,9205,485000000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
5,690
125,754
5,485
221,920
0
225,565
228,355
230,799
307,871
308,830
311,354
316,519
327,628
458,866
469,627
474,648
499,715
539,920
550,898
556,224
559,126
569,974
571,814
573,398
606,182
625,124
629,558
632,001
636,910
636,910632,001629,558625,124606,182573,398571,814569,974559,126556,224550,898539,920499,715474,648469,627458,866327,628316,519311,354308,830307,871230,799228,355225,5650221,9205,485125,7545,6900000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-303
Gross Profit-303-303
 
Operating Income (+$)
Gross Profit-303
Operating Expense-38,850
Operating Income-39,153-39,153
 
Operating Expense (+$)
Research Development18,586
Selling General Administrative21,775
Selling And Marketing Expenses0
Operating Expense38,85040,361
 
Net Interest Income (+$)
Interest Income2,455
Interest Expense-5,814
Other Finance Cost-109
Net Interest Income-3,468
 
Pretax Income (+$)
Operating Income-39,153
Net Interest Income-3,468
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-42,199-36,107
EBIT - interestExpense = -44,967
-42,199
-36,385
Interest Expense5,814
Earnings Before Interest and Taxes (EBIT)-39,153-36,385
Earnings Before Interest and Taxes (EBITDA)-38,850
 
After tax Income (+$)
Income Before Tax-42,199
Tax Provision-0
Net Income From Continuing Ops-46,415-42,199
Net Income-42,199
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses39,153
Total Other Income/Expenses Net-3,0463,468
 

Technical Analysis of Kala Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kala Pharmaceuticals Inc. The general trend of Kala Pharmaceuticals Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kala Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kala Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 8.12 < 8.23 < 9.25.

The bearish price targets are: 6.735 > 6.73 > 6.485.

Tweet this
Kala Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kala Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kala Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kala Pharmaceuticals Inc. The current macd is -0.19059218.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kala Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kala Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kala Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kala Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartKala Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kala Pharmaceuticals Inc. The current adx is 28.53.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kala Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Kala Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kala Pharmaceuticals Inc. The current sar is 7.50094629.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kala Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kala Pharmaceuticals Inc. The current rsi is 28.20. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Kala Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartKala Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kala Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kala Pharmaceuticals Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Kala Pharmaceuticals Inc Daily Stochastic Oscillator ChartKala Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kala Pharmaceuticals Inc. The current cci is -149.55479282.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Kala Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartKala Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kala Pharmaceuticals Inc. The current cmo is -68.44561765.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kala Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartKala Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kala Pharmaceuticals Inc. The current willr is -89.11564626.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Kala Pharmaceuticals Inc Daily Williams %R ChartKala Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kala Pharmaceuticals Inc.

Kala Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kala Pharmaceuticals Inc. The current atr is 0.29835284.

Kala Pharmaceuticals Inc Daily Average True Range (ATR) ChartKala Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kala Pharmaceuticals Inc. The current obv is 140,722,971.

Kala Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartKala Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kala Pharmaceuticals Inc. The current mfi is 8.51480796.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Kala Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartKala Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kala Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Kala Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kala Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.203
Ma 20Greater thanMa 507.549
Ma 50Greater thanMa 1007.441
Ma 100Greater thanMa 2007.298
OpenGreater thanClose6.900
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kala Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Kala Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kala Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kala Pharmaceuticals Inc

I send you an email if I find something interesting about Kala Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kala Pharmaceuticals Inc.

Receive notifications about Kala Pharmaceuticals Inc in your mailbox!